iTeos, GSK Results in Non-Small Cell Lung Cancer

 Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose

- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy
- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations
- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting
- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET

The follow-up interim data from GALAXIES Lung-201 will be discussed during a conference call and webcast presentation on Monday, September 16th, 2024 at 8:00AM ET. To register for the webcast presentation, please visit the Events section on the Investors page of the iTeos website at investors.iteostherapeutics.com. A webcast replay may be accessed on the Investors section of the iTeos website.

https://www.globenewswire.com/news-release/2024/09/14/2946227/0/en/iTeos-Announces-Clinically-Meaningful-Objective-Response-Rate-Observed-at-Every-Dose-in-Follow-up-Interim-Analysis-of-GALAXIES-Lung-201-Study-of-Belrestotug-Dostarlimab-in-First-Li.html